AccurKardia, Inc.

AccurKardia is an ECG-led diagnostics software company headquartered in New York, NY, United States. Established in 2019, the company's core mission is to leverage artificial intelligence to interpret electrocardiogram (ECG) signals, transforming them into a comprehensive diagnostic tool and biomarker to improve patient outcomes and save lives globally.

The company's primary offering is the AccurECG™ Analysis System, an FDA-cleared Class II Software as a Medical Device (SaMD) that provides automated, near real-time ECG interpretation. This cloud-based, device-agnostic platform is designed to detect up to 13 arrhythmias and is utilized by cardiac monitoring companies, device manufacturers, hospitals, and independent diagnostic testing facilities. AccurKardia also develops investigational AI-driven solutions, including AK-AVS™ for aortic valve stenosis screening and AK+ Guard™ for hyperkalemia detection, both of which have received FDA Breakthrough Device Designation.

In January 2026, AccurKardia secured FDA 510(k) clearance for its AccurECG 2.0, an enterprise-grade platform designed for high-volume ECG data processing with approximately 99% accuracy. The company has also been granted a U.S. patent for its AI-driven ECG detection of cardiac amyloidosis in June 2026. Led by Co-Founder and CEO Juan C. Jimenez, AccurKardia has recently formed strategic collaborations with companies like Wellysis and HeartBeam to further integrate its ECG analytics into remote cardiac monitoring solutions, aiming to address clinical backlogs and expand access to cardiac care.